Galapagos NV : Galapagos announces GSK2586184 JAK1 molecule progresses to
Phase 2 studies
Mechelen, Belgium; 5 February 2013 - Galapagos NV (Euronext: GLPG) announced
today that GlaxoSmithKline plan to initiate Phase 2 studies with GSK2586184
(formerly GLPG0778) in systemic lupus erythematosus (SLE) and chronic plaque
psoriasis. GSK2586184 is the second selective JAK1 molecule discovered by
Galapagos to enter Phase 2 studies.
GSK2586184 is a selective JAK1 inhibitor which was discovered and developed
within Galapagos' osteoarthritis alliance with GSK. GSK in-licensed the
molecule in February 2012, gaining worldwide rights to further development and
commercialization. Galapagos is eligible, without further financial
investment from Galapagos, to receive from GSK €34M in additional milestones
plus up to double-digit royalties on global commercial sales of all
therapeutic indications of GSK2586184.
"Inhibition of JAK1 is considered a promising new therapeutic route to treat
inflammatory diseases. Galapagos is leading the field with two JAK1
inhibition molecules being tested in patients," said Onno van de Stolpe, CEO
of Galapagos. "With two of our JAK1 molecules in Phase 2, we hope that this
will deliver a new class of medicines to patients with inflammatory diseases."
GSK plans to initiate a 12 week, multi-center, dose-ranging,
placebo-controlled Phase 2 study investigating safety and efficacy of various
doses of GSK2586184 in SLE patients. Furthermore, GSK will also initiate a 12
week multi-center, dose-ranging, placebo-controlled Phase 2 study
investigating the efficacy and safety of GSK2586184 in chronic plaque
About Systemic lupus erythematosus
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by
inflammation of many parts of the body. This inflammation is caused by the
immune system that mistakenly attacks healthy cells, leading to tissue damage.
The cause remains unknown, but SLE occurs more often in women, especially at
childbearing age. SLE is more common in those of non-European descent, with
prevalence ranges of 20 to 150 cases per 100.000 persons. Joint pain, muscle
pain, fever, fatigue and malaise are the most common symptoms, and these can
come and go unpredictably. Because these complaints are often observed with
other diseases, diagnosis of SLE is difficult. Currently there is no cure for
SLE, but the symptoms can be controlled by medicines, the most common of which
are non-steroidal anti-inflammatory drugs (NSAID) and anti-malarial medicines.
Those with more serious illness may require corticosteroids,
immunosuppressants, but these have side-effects and are not always effective.
Psoriasis is an immune-mediated disease that affects the skin. It is caused
by the immune system being mistakenly triggered, resulting in overproduction
of new skin cells. The cause is not fully understood, but it is believed to
have a genetic component and certain medications and infections are well-known
risk factors. Psoriasis affects approximately 3% of people globally and it
can occur at any age, although it most commonly appears for the first time
between the ages of 15 and 25 years. There are five types of psoriasis with
the most common form being plaque psoriasis, characterized by red patches
covered by a silvery white scale appearing on the top first layer of the skin.
Psoriasis can also cause inflammation of the joints, which is known as
psoriatic arthritis, affecting between 10-30% of all people with psoriasis.
Psoriasis is typically a lifelong condition and there is currently no cure,
but various treatments can help to control the symptoms. Treating moderate to
severe psoriasis usually involves a combination of treatment strategies:
topical treatments, light therapy and/or systemic medications, including
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline of four clinical, six pre-clinical, and
30 discovery small-molecule and antibody programs in cystic fibrosis,
inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about to
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license
agreement whereby AbbVie will be responsible for further development and
commercialization after Phase 2b. Galapagos has another selective JAK1
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778,
in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin
receptor antagonist currently in a Phase 1b patient study in metastasis.
GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically for the
treatment of IBD; this program will start a Proof of Concept Phase 2 study in
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has over 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information at:
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
Galapagos announces GSK2586184 progresses to Phase 2 studies
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.